Concentration-dependent changes in the susceptibility and killing of Staphylococcus aureus in an in vitro dynamic model that simulates normal and impaired gatifloxacin elimination

被引:17
作者
Firsov, AA
Vostrov, SN
Lubenko, IY
Zinner, SH
Portnoy, YA
机构
[1] Russian Acad Med Sci, Gause Inst New Antibiot, Dept Phamacokinet & Pharmacodynam, Moscow 119021, Russia
[2] Harvard Univ, Sch Med, Mt Auburn Hosp, Dept Med, Cambridge, MA 02138 USA
关键词
bacterial resistance; fluoroquinolones; pharmacokinetics;
D O I
10.1016/j.ijantimicag.2003.06.001
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
To demonstrate the impact of normal (NEK) and impaired elimination kinetics (IEK) of gatifloxacin on its ability to protect from losses in the susceptibility of Staphylococcus aureus, a clinical isolate of methicillin-resistant S. aureus at a starting inoculum of 10(8) cfu/ml was exposed to 3 days of quinolone dosing. A series of monoexponential pharmacokinetic profiles with half-lives of 7 h (NEK) and 31 h (IEK) were simulated over 32- and 8-fold ranges of the 24 h area under the concentration-time curve (AUC(24))-to-MIC ratio, respectively. The simulated AUC(24)/MICS were designed to provide peak concentrations (C(max)s) close to the MIC, between the MIC and the mutant prevention concentration (MPC), i.e., within the mutant selection window (MSW), and above the MPC. With both NEK and IEK simulations, significant increases in MIC were observed at those AUC24/MICS that correspond to gatifloxacin concentrations within the MSW over most of the dosing interval (>25%). No such increases were observed at the smallest AUC(24)/MIC (10 h with NEK and 20 h with IEK) when the simulated C(max)s were close to the MIC, with minimal if any bacterial killing, and at the highest AUC(24)/MICS (310 and 160 h, respectively) when gatifloxacin concentrations exceeded the MPC over most of the dosing interval, with maximal antimicrobial effect. These 'protective' AUC(24)/MIC ratios correspond to 135% of the usual gatifloxacin clinical dose (400 mg IEK) and 60% of the loading and maintenance doses (400 mg, then 200 mg IEK). This study predicts different protective potentials of gatifloxacin in IEK and NEK against staphylococcal resistance and supports the MSW concept. (C) 2003 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:60 / 66
页数:7
相关论文
共 22 条
[1]   The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus aureus in an in-vitro infection model [J].
Aeschlimann, JR ;
Kaatz, GW ;
Rybak, MJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (03) :343-349
[2]   Activities of newer fluoroquinolones against ciprofloxacin resistant Streptococcus pneumoniae [J].
Coyle, EA ;
Kaatz, GW ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1654-1659
[3]   Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses [J].
Firsov, AA ;
Zinner, SH ;
Lubenko, IY ;
Vostrov, SN .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2000, 16 (04) :407-414
[4]   Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model:: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses [J].
Firsov, AA ;
Lubenko, IY ;
Vostrov, SN ;
Kononenko, OV ;
Zinner, SH ;
Portnoy, YA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (05) :725-732
[5]   Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model [J].
Firsov, AA ;
Vasilov, RG ;
Vostrov, SN ;
Kononenko, OV ;
Lubenko, IY ;
Zinner, SH .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (04) :483-490
[6]   Quantitative analysis of antimicrobial effect kinetics in an in vitro dynamic model [J].
FIRSOV, AA ;
CHERNYKH, VM ;
NAVASHIN, SM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (07) :1312-1317
[7]   Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: Action of ciprofloxacin against Escherichia coli in an in vitro dynamic model [J].
Firsov, AA ;
Vostrov, SN ;
Shevchenko, AA ;
Cornaglia, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) :1281-1287
[8]   Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: New insight into a widely used concept [J].
Firsov, AA ;
Shevchenko, AA ;
Vostrov, SN ;
Zinner, SH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (03) :659-665
[9]   In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus [J].
Firsov, AA ;
Vostrov, SN ;
Lubenko, IY ;
Drlica, K ;
Portnoy, YA ;
Zinner, SH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (05) :1604-1613
[10]   PHARMACOKINETIC AND PHARMACODYNAMIC ACTIVITIES OF CIPROFLOXACIN AGAINST STRAINS OF STREPTOCOCCUS-PNEUMONIAE, STAPHYLOCOCCUS-AUREUS, AND PSEUDOMONAS-AERUGINOSA FOR WHICH MICS ARE SIMILAR [J].
HYATT, JM ;
NIX, DE ;
SCHENTAG, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (12) :2730-2737